Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

When deviations or disturbances occur in continuous bioprocessing, determining the exact volume of impacted material downstream is difficult. Through first-principle CFD and rapid response models across stirred tanks, connectors, filters, and chromatography units, teams can simulate the whole residence time distribution chain to pinpoint precisely which product must be discarded and which can be retained safely.

Related Insights

Instead of waiting for physical tech transfer runs, biotech startups can use CFD to determine whether a process refined in micro-bioreactors will run safely in a CDMO's specific reactor fleet. Performing this virtual scale-up in advance derisks facility selection, reduces timeline and financial commitments, and provides verifiable technical proof for prospective investors.

Christian Witz notes that biotech scientists frequently treat CFD as an intimidating tool requiring a dedicated physics or mathematics PhD. However, the real obstacle is that conventional CFD user interfaces have not been tailored to bioprocess workflows. Just as modern computer use does not require an IT technician, tailored interfaces allow routine process development scientists to employ CFD daily like Excel.

Manage the complexity of end-to-end continuous processes by creating automated feedback loops. Integrating real-time analytics, like an online HPLC, with mechanistic models allows for the dynamic, on-the-fly adjustment of downstream unit operations based on live upstream performance, optimizing the entire system.

Because CFD operates strictly on physical parameters rather than biological mechanisms, a vessel needs to be fully characterized only once across 100 to 200 operational points. When switching to a new molecule, media, or cell line, the scale-up software only needs updated fluid properties such as viscosity, density, surface tension, and salt concentration, eliminating the need to re-run simulations from scratch.

Early CFD adoption in biotech faltered because limited compute power forced engineers to use geometric simplifications, such as simulating a single periodic cake slice instead of the entire reactor cylinder. Bioreactors contain massive three-dimensional wrapping flows that cannot be captured in periodic wedge models. These simplifications produced inaccurate results, leading teams to experience poor outcomes and abandon simulation for years.

By training on multi-scale data from lab, pilot, and production runs, AI can predict how parameters like mixing and oxygen transfer will change at larger volumes. This enables teams to proactively adjust processes, moving from 'hoping' a process scales to 'knowing' it will.

Conventional scale-up rules of thumb, such as constant power per volume, fail to accurately reproduce cellular microenvironments when working with shear-sensitive cell therapies or delicate organisms like Streptomyces. By simulating and matching comprehensive physical parameters across vessels using CFD, teams achieve far more comparable cell morphology and reliable cell growth without relying on protective additives like antifoam.

Massive CFD simulation datasets can be distilled into compact reduced-order surrogate models of just a few megabytes using machine learning. Rather than sifting through overwhelming data files, the model interpolates between simulated test points to predict key bioreactor parameters—including kLa, shear rate distribution, and mixing times—in milliseconds for any given operating condition.

The future of bioprocess development involves using AI on high-throughput data for predictive modeling. This, combined with in silico simulations (digital twins), will allow scientists to understand underlying biological mechanisms, not just identify optimal conditions, dramatically accelerating optimization.

AI models mirror a bioreactor in real time, creating a "digital twin." This allows operators to test process changes and potential failure modes virtually, without touching the actual, expensive physical system, much like having a virtual engineer working alongside them.

Residence Time Distribution Modeling Prevents Unnecessary Product Discard in Continuous Bioprocessing Deviations | RiffOn